BriaCell Receives FDA Clearance to Initiate Bria-PROS+(TM) Clinical Study in Prostate Cancer

BriaCell Therapeutics announced that the US FDA has completed its review of the Investigational New Drug application for Bria-PROS+ and issued a Study May Proceed letter, clearing the way for clinical evaluation of Bria-PROS+, its next generation, personalized, off-the-shelf, cell-based immunotherapy for prostate cancer.